Stem Cell Clinic

Equillium Announces Pricing of $30 Million Registered Direct Offering

By Global News Feed

LA JOLLA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase agreement with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit is $7.00, priced above the market under Nasdaq rules. The warrants will have an exercise price of $14.00 per share, will be immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.

Read this article:
Equillium Announces Pricing of $30 Million Registered Direct Offering

Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium

By Global News Feed

BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that it will present three late-breaker abstracts at the 17th annual WORLDSymposium, a research conference dedicated to lysosomal diseases being held virtually February 8-12, 2021. The poster presentations will highlight data supporting Gain’s Gaucher disease, GM1 gangliosidosis and Morquio B programs.

See the rest here:
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium

Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

By Global News Feed

LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced positive preliminary results from its Phase 1 trial of iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through its subsidiary, AgenTus Therapeutics.

Read the original:
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

ACTIVE BIOTECH ENTERS INTO A MANUFACTURING AGREEMENT WITH FAMAR HEALTH CARE SERVICES FOR NEW FORMULATION OF LAQUINIMOD

By Global News Feed

Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) today announced it has reached a manufacturing agreement with Famar Health Care Services Madrid SAU (“Famar”), a European provider of pharmaceutical manufacturing and development services. Famar will deliver clinical trial material of the newly developed eye-drop formulation of laqui­nimod.

View original post here:
ACTIVE BIOTECH ENTERS INTO A MANUFACTURING AGREEMENT WITH FAMAR HEALTH CARE SERVICES FOR NEW FORMULATION OF LAQUINIMOD

Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide

By Global News Feed

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.

Read the original:
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide

→←